LEXICON PHARMACEUTICALS, INC. - Common Stock, par value $0.001 per share (LXRX)

CUSIP: 528872302

Q1 2025 13F Holders as of 31 Mar 2025

Type / Class
Equity / Common Stock, par value $0.001 per share
Shares outstanding
444,558,533
Total 13F shares
265,818,368
Share change
-30,807,274
Total reported value
$122,485,430
Put/Call ratio
24%
Price per share
$0.46
Number of holders
124
Value change
-$18,132,306
Number of buys
64
Number of sells
61

Quarterly Holders Quick Answers

What is CUSIP 528872302?
CUSIP 528872302 identifies LXRX - LEXICON PHARMACEUTICALS, INC. - Common Stock, par value $0.001 per share in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Top shareholders of LXRX - LEXICON PHARMACEUTICALS, INC. - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Holder Source Role / Reporting Ownership % Shares Holdings Value 12M Net Δ As of Details
Artal Group S.A.
13F
Company
31%
136,180,481
$100,773,556 31 Dec 2024
13F
Siren, L.L.C.
3/4/5 13F
Director, 10%+ Owner · Individual
8.8%
from 13F
35,402,689
$92,755,045 25 Jul 2024
FMR LLC
13F
Company
12%
51,970,455
$38,380,181 31 Dec 2024
13F
BlackRock, Inc.
13F
Company
2.3%
10,333,158
$7,631,037 31 Dec 2024
13F
VANGUARD GROUP INC
13F
Company
2.2%
9,881,728
$7,302,597 31 Dec 2024
13F
Point72 Asset Management, L.P.
13F
Company
2%
8,988,421
$6,637,949 31 Dec 2024
13F
Invus US Partners LLC
3/4/5
Director, 10%+ Owner
class O/S missing
5,782,749
$6,090,969 05 Aug 2022
Schonfeld Strategic Advisors LLC
13F
Company
1.7%
7,558,621
$5,582,040 31 Dec 2024
13F
Nantahala Capital Management, LLC
13F
Company
1.5%
6,604,150
$4,877,165 31 Dec 2024
13F
Lonnel Coats
3/4/5
Chief Executive Officer, Director
mixed-class rows
2,109,255
mixed-class rows
$3,507,748 28 Feb 2024
GEODE CAPITAL MANAGEMENT, LLC
13F
Company
0.79%
3,521,255
$2,601,084 31 Dec 2024
13F
STATE STREET CORP
13F
Company
0.61%
2,718,248
$2,007,426 31 Dec 2024
13F
NEA Management Company, LLC
13F
Company
0.54%
2,382,286
$1,759,318 31 Dec 2024
13F
Ikarian Capital, LLC
13F
Company
0.35%
1,550,000
$1,144,675 31 Dec 2024
13F
Jeffrey L. Wade
3/4/5
President and COO
mixed-class rows
729,441
mixed-class rows
$1,106,796 08 Jul 2024
PINNACLE ASSOCIATES LTD
13F
Company
0.32%
1,425,292
$1,052,578 31 Dec 2024
13F
NORTHERN TRUST CORP
13F
Company
0.29%
1,308,651
$966,439 31 Dec 2024
13F
CHARLES SCHWAB INVESTMENT MANAGEMENT INC
13F
Company
0.27%
1,191,091
$879,621 31 Dec 2024
13F
Nuveen Asset Management, LLC
13F
Company
0.25%
1,103,840
$815,186 31 Dec 2024
13F
Hennion & Walsh Asset Management, Inc.
13F
Company
0.19%
863,255
$637,514 31 Dec 2024
13F
TANG CAPITAL MANAGEMENT LLC
13F
Company
0.19%
850,268
$627,923 31 Dec 2024
13F
B. Kassler Taub
3/4/5
SVP, Regulatory & QA
mixed-class rows
431,995
mixed-class rows
$597,845 28 Feb 2024
WELLINGTON MANAGEMENT GROUP LLP
13F
Company
0.17%
747,996
$552,395 31 Dec 2024
13F
UBS Group AG
13F
Company
0.15%
686,117
$507,040 31 Dec 2024
13F
SUSQUEHANNA INTERNATIONAL GROUP, LLP
13F
Company
0.12%
550,891
$406,833 31 Dec 2024
13F
GOLDMAN SACHS GROUP INC
13F
Company
0.12%
540,207
$398,942 31 Dec 2024
13F
MORGAN STANLEY
13F
Company
0.12%
526,150
$388,562 31 Dec 2024
13F
BOOTHBAY FUND MANAGEMENT, LLC
13F
Company
0.11%
480,822
$355,087 31 Dec 2024
13F
BBR PARTNERS, LLC
13F
Company
0.11%
470,000
$347,095 31 Dec 2024
13F
Ph.D. Alan J. Main
3/4/5
EVP, Innov & Chem Sciences
mixed-class rows
1,228,681
mixed-class rows
$318,646 28 Feb 2025
Swiss National Bank
13F
Company
0.1%
426,600
$315,044 31 Dec 2024
13F
VIRTUS ADVISERS, LLC
13F
Company
0.1%
425,269
$314,061 31 Dec 2024
13F
Brian T. Corrigan
3/4/5
SVP, Regulatory & QA
mixed-class rows
1,121,660
mixed-class rows
$300,602 13 Feb 2025
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC
13F
Company
0.08%
353,508
$261,242 31 Dec 2024
13F
Thomas Garner
3/4/5
SVP, Chief Commercial Officer
mixed-class rows
454,260
mixed-class rows
$239,236 08 Feb 2024
DEUTSCHE BANK AG\
13F
Company
0.07%
315,659
$233,587 31 Dec 2024
13F
Bank of New York Mellon Corp
13F
Company
0.07%
314,919
$232,569 31 Dec 2024
13F
GROUP ONE TRADING LLC
13F
Company
0.07%
314,404
$232,187 31 Dec 2024
13F
Robert J. Lefkowitz MD
3/4/5
Director
mixed-class rows
130,080
mixed-class rows
$223,156 13 May 2024
ALLIANCEBERNSTEIN L.P.
13F
Company
0.06%
246,121
$181,760 31 Dec 2024
13F
BARCLAYS PLC
13F
Company
0.05%
243,316
$179,690 31 Dec 2024
13F
Woodline Partners LP
13F
Company
0.05%
229,376
$169,394 31 Dec 2024
13F
JANE STREET GROUP, LLC
13F
Company
0.05%
220,264
$162,665 31 Dec 2024
13F
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
13F
Company
0.04%
195,215
$144,166 31 Dec 2024
13F
RHUMBLINE ADVISERS
13F
Company
0.03%
153,151
$113,013 31 Dec 2024
13F
Ph.D. Kiernan Seth
3/4/5
VP, Chief Commercial Officer
mixed-class rows
379,163
mixed-class rows
$104,343 28 Feb 2023
BANK OF AMERICA CORP /DE/
13F
Company
0.03%
136,407
$100,669 31 Dec 2024
13F
STIFEL FINANCIAL CORP
13F
Company
0.03%
112,853
$83,344 31 Dec 2024
13F
Legal & General Group Plc
13F
Company
0.03%
111,403
$82,271 31 Dec 2024
13F
Lombard Odier SCmA Compagnie
13F
Individual
0.02%
110,000
$81,235 31 Dec 2024
13F

Institutional Holders of LEXICON PHARMACEUTICALS, INC. - Common Stock, par value $0.001 per share (LXRX) as of Q1 2025

As of 31 Mar 2025, LEXICON PHARMACEUTICALS, INC. - Common Stock, par value $0.001 per share (LXRX) was held by 124 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 265,818,368 shares. The largest 10 holders included Artal Group S.A., Siren, L.L.C., FMR LLC, BlackRock, Inc., VANGUARD GROUP INC, Schonfeld Strategic Advisors LLC, GEODE CAPITAL MANAGEMENT, LLC, STATE STREET CORP, CIBC Private Wealth Group LLC, and UBS Group AG. This page lists 123 institutional shareholders reporting positions in this security for the Q1 2025 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period

Compare Q1 2025 vs Q4 2024 Across Filers

Q4 2024 holders
124
Q1 2025 holders
124
Holder diff
0
Investor Q4 2024 Shares Q1 2025 Shares Share Diff Share Chg % Q4 2024 Value $ Q1 2025 Value $ Value Diff $ Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .